SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease.

EBioMedicine · 2021-05-14

DOI: 10.1016/j.ebiom.2021.103380PMID: 34000620

Open accessresearch-article; Clinical Trial, Phase I; Journal ArticleOriginal source ↗

Research overview

Source publication and reading guides

This section identifies the original publication. Follow the source for its authors and journal.

Read the original publication ↗

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.